Hawthorn Berry for Heart Failure: A European Mainstay

← Back to articles

Hawthorn (Crataegus species) extracts have been used in European cardiology for over a century for mild heart failure and angina. The standardised extract WS 1442 is prescribed as a drug in Germany and several other EU countries with reimbursement. Its evidence base is more substantial than most supplement consumers realise.

The SPICE Trial

The SPICE trial (n=2,681) randomised patients with NYHA class II/III heart failure to WS 1442 900 mg/day or placebo in addition to standard therapy. Over 2 years, the primary endpoint (cardiac death, MI, hospitalisation for heart failure) was not reduced overall, but prespecified subgroup analyses showed significant reductions in sudden cardiac death in patients with LVEF 25–35%. The interpretation is that hawthorn adds modest benefit on top of modern heart failure therapy in specific subgroups.

Symptomatic Benefit

A 2008 Cochrane review of 14 earlier RCTs in mild-to-moderate heart failure (n=855) found hawthorn extract improved exercise tolerance (pressure-rate product) and reduced subjective symptoms (fatigue, dyspnoea) compared to placebo. Effect sizes were modest. These trials predated widespread ACE inhibitor and beta-blocker use, so the evidence applies most directly to an earlier era of heart failure management.

Mechanism

Hawthorn’s active compounds (oligomeric procyanidins, flavonoids) weakly inhibit phosphodiesterase-3, enhance endothelial function, and modulate ion channels. The net effect is mild positive inotropy without increased myocardial oxygen demand — pharmacologically sensible in heart failure.

Where It Fits Today

Modern heart failure therapy (beta-blockers, ACE/ARB, mineralocorticoid antagonists, SGLT2 inhibitors, sacubitril/valsartan) provides very large mortality benefits. Hawthorn should never replace these. As an add-on for symptomatic relief in patients already on optimal therapy, the evidence is modest but supportive. WS 1442 at 900 mg/day is the tested dose.

Safety

Well tolerated in trials — main side effects are mild GI upset and occasional dizziness. Some additive effects with digoxin, nitrates, and antihypertensives; coordinate with prescribing clinician. Stop 2 weeks before surgery due to theoretical effects on cardiac electrophysiology.